Product Wiki · Recalls · Health Canada — Marketed Health Products

Archived - New Safety Information Regarding Liver Injury and Hypersensitivity Associated with TYSABRI™ (natalizumab) - For the Public — recall 22810

Health Canada — Marketed Health Products · Canada · 2008-06-06

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Agency
Health Canada — Marketed Health Products
Recall identifier
22810
Date of alert
2008-06-06
Country / jurisdiction
Canada
Risk type
recall
Product category
Biologic or vaccine
Product type
Marketed health products
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/archived-new-safety-informatio

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.